Circulating miRNA Correlates with Lipid Profile and Disease Activity in Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients.
Krzysztof BonekEwa Kuca WarnawinAnna KornatkaMagdalena PlebańczykTomasz BurakowskiWłodzimierz MaślińskiMałgorzata WisłowskaPiotr GłuszkoMarzena CiechomskaPublished in: Biomedicines (2022)
This study aimed to investigate the associations of microRNA (miRs) signatures with cytokines, serum lipids, and disease activity in patients with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and rheumatoid arthritis (RA). In total, 65 patients (PsA n = 25, AS n = 25, RA n = 15) and 25 healthy controls (HC) were enrolled into the study. The expression of miR-223-5p, miR-92b-3p, miR-485-3p, miR-10b-5p, let-7d-5p, miR-26a-2-3p, miR-146b-3p, and cytokines levels were measured in sera. DIANA-mirPath analysis was used to predict pathways targeted by the dysregulated miRs. Disease activity scores were calculated. Lipid profile, uric acid, glucose level, and C-reactive protein (CRP) concentrations were determined in the blood. Based on lipid profiles, the PsA group had hypertriglyceridaemia, and RA patients revealed mixed dyslipidaemia, while in AS, no specific changes were found. miR expression analysis revealed upregulation of miR-26a-2-3p and miR-10b-5p in PsA, miR-485-3p in AS, and let-7d-5p in RA. Several correlations between disease activity indexes, metabolites levels, and expression of miRs were observed in PsA, RA, and AS patients. Finally, in ROC analysis, miR-26a-2-3p/miR-485-3p, and let-7d-5p/miR-146b-3p tandems revealed high sensitivity and specificity in distinguishing between PsA, AS, and RA. Our study illustrates the superiority of miR expressions in distinguishing between RA, PsA, and AS. In PsA, a unique regulatory pathway exists through miR-26a-2-3p, miR-223-5p, miR-10b-5p, and miR-92b-3p that converges proatherogenic metabolism and disease activity.
Keyphrases
- disease activity
- rheumatoid arthritis
- ankylosing spondylitis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- prostate cancer
- juvenile idiopathic arthritis
- end stage renal disease
- ejection fraction
- newly diagnosed
- radical prostatectomy
- chronic kidney disease
- cell proliferation
- uric acid
- peritoneal dialysis
- interstitial lung disease
- prognostic factors
- blood pressure
- dna methylation
- type diabetes
- patient reported outcomes
- transcription factor
- drug delivery
- cancer therapy
- blood glucose
- binding protein
- systemic sclerosis
- patient reported